دورية أكاديمية
What Is the Economic Benefit of Annual COVID-19 Vaccination From the Adult Individual Perspective?
| العنوان: | What Is the Economic Benefit of Annual COVID-19 Vaccination From the Adult Individual Perspective? |
|---|---|
| المؤلفون: | Bartsch SM; Public Health Informatics, Computational, and Operations Research, Graduate School of Public Health and Health Policy, City University of New York, New York City, New York, USA.; Center for Advanced Technology and Communication in Health, Graduate School of Public Health and Health Policy, City University of New York, New York City, New York, USA.; Pandemic Response Institute, New York City, New York, USA., O'Shea KJ; Public Health Informatics, Computational, and Operations Research, Graduate School of Public Health and Health Policy, City University of New York, New York City, New York, USA.; Center for Advanced Technology and Communication in Health, Graduate School of Public Health and Health Policy, City University of New York, New York City, New York, USA.; Pandemic Response Institute, New York City, New York, USA., Weatherwax C; Public Health Informatics, Computational, and Operations Research, Graduate School of Public Health and Health Policy, City University of New York, New York City, New York, USA.; Center for Advanced Technology and Communication in Health, Graduate School of Public Health and Health Policy, City University of New York, New York City, New York, USA.; Pandemic Response Institute, New York City, New York, USA., Strych U; National School of Tropical Medicine, Department of Pediatrics, and Texas Children's Hospital Center for Vaccine Development, Baylor College of Medicine, Houston, Texas, USA., Velmurugan K; Public Health Informatics, Computational, and Operations Research, Graduate School of Public Health and Health Policy, City University of New York, New York City, New York, USA.; Center for Advanced Technology and Communication in Health, Graduate School of Public Health and Health Policy, City University of New York, New York City, New York, USA.; Pandemic Response Institute, New York City, New York, USA., John DC; Public Health Informatics, Computational, and Operations Research, Graduate School of Public Health and Health Policy, City University of New York, New York City, New York, USA.; Center for Advanced Technology and Communication in Health, Graduate School of Public Health and Health Policy, City University of New York, New York City, New York, USA.; Pandemic Response Institute, New York City, New York, USA., Bottazzi ME; National School of Tropical Medicine, Department of Pediatrics, and Texas Children's Hospital Center for Vaccine Development, Baylor College of Medicine, Houston, Texas, USA.; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA., Hussein M; Graduate School of Public Health and Health Policy, City University of New York, New York City, New York, USA., Martinez MF; Public Health Informatics, Computational, and Operations Research, Graduate School of Public Health and Health Policy, City University of New York, New York City, New York, USA.; Center for Advanced Technology and Communication in Health, Graduate School of Public Health and Health Policy, City University of New York, New York City, New York, USA.; Pandemic Response Institute, New York City, New York, USA., Chin KL; Public Health Informatics, Computational, and Operations Research, Graduate School of Public Health and Health Policy, City University of New York, New York City, New York, USA.; Center for Advanced Technology and Communication in Health, Graduate School of Public Health and Health Policy, City University of New York, New York City, New York, USA.; Pandemic Response Institute, New York City, New York, USA., Ciciriello A; National School of Tropical Medicine, Department of Pediatrics, and Texas Children's Hospital Center for Vaccine Development, Baylor College of Medicine, Houston, Texas, USA., Heneghan J; Public Health Informatics, Computational, and Operations Research, Graduate School of Public Health and Health Policy, City University of New York, New York City, New York, USA.; Center for Advanced Technology and Communication in Health, Graduate School of Public Health and Health Policy, City University of New York, New York City, New York, USA.; Pandemic Response Institute, New York City, New York, USA., Dibbs A; Public Health Informatics, Computational, and Operations Research, Graduate School of Public Health and Health Policy, City University of New York, New York City, New York, USA.; Center for Advanced Technology and Communication in Health, Graduate School of Public Health and Health Policy, City University of New York, New York City, New York, USA.; Pandemic Response Institute, New York City, New York, USA., Scannell SA; Public Health Informatics, Computational, and Operations Research, Graduate School of Public Health and Health Policy, City University of New York, New York City, New York, USA.; Center for Advanced Technology and Communication in Health, Graduate School of Public Health and Health Policy, City University of New York, New York City, New York, USA.; Pandemic Response Institute, New York City, New York, USA., Hotez PJ; National School of Tropical Medicine, Department of Pediatrics, and Texas Children's Hospital Center for Vaccine Development, Baylor College of Medicine, Houston, Texas, USA.; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA., Lee BY; Public Health Informatics, Computational, and Operations Research, Graduate School of Public Health and Health Policy, City University of New York, New York City, New York, USA.; Center for Advanced Technology and Communication in Health, Graduate School of Public Health and Health Policy, City University of New York, New York City, New York, USA.; Pandemic Response Institute, New York City, New York, USA.; Graduate School of Public Health and Health Policy, City University of New York, New York City, New York, USA. |
| المصدر: | The Journal of infectious diseases [J Infect Dis] 2024 Aug 16; Vol. 230 (2), pp. 382-393. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Jan. 2011- : Oxford : Oxford University Press Original Publication: 1904-2010 : Chicago, IL : University of Chicago Press |
| مواضيع طبية MeSH: | COVID-19*/prevention & control , COVID-19*/economics , COVID-19*/epidemiology , COVID-19 Vaccines*/economics , COVID-19 Vaccines*/administration & dosage , SARS-CoV-2*/immunology , Vaccination*/economics , Cost-Benefit Analysis* , Markov Chains*, Humans ; Middle Aged ; Adult ; Adolescent ; Young Adult ; United States/epidemiology ; Male ; Female |
| مستخلص: | Background: With coronavirus disease 2019 (COVID-19) vaccination no longer mandated by many businesses/organizations, it is now up to individuals to decide whether to get any new boosters/updated vaccines going forward. Methods: We developed a Markov model representing the potential clinical/economic outcomes from an individual perspective in the United States of getting versus not getting an annual COVID-19 vaccine. Results: For an 18-49 year old, getting vaccinated at its current price ($60) can save the individual on average $30-$603 if the individual is uninsured and $4-$437 if the individual has private insurance, as long as the starting vaccine efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is ≥50% and the weekly risk of getting infected is ≥0.2%, corresponding to an individual interacting with 9 other people in a day under Winter 2023-2024 Omicron SARS-CoV-2 variant conditions with an average infection prevalence of 10%. For a 50-64 year old, these cost-savings increase to $111-$1278 and $119-$1706 for someone without and with insurance, respectively. The risk threshold increases to ≥0.4% (interacting with 19 people/day), when the individual has 13.4% preexisting protection against infection (eg, vaccinated 9 months earlier). Conclusions: There is both clinical and economic incentive for the individual to continue to get vaccinated against COVID-19 each year. Competing Interests: Potential conflicts of interest . P. J. H., M. E. B., and U. S. are coinventors of a COVID-19 recombinant protein vaccine technology owned by Baylor College of Medicine (BCM) that was recently licensed by BCM nonexclusively and with no patent restrictions to several companies committed to advance vaccines for low- and middle-income countries. The coinventors have no involvement in license negotiations conducted by BCM. Similar to other research universities, a long-standing BCM policy provides its faculty and staff, who make discoveries that result in a commercial license, a share of any royalty income, according to BCM policy. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.) |
| References: | MMWR Morb Mortal Wkly Rep. 2023 May 05;72(18):493-496. (PMID: 37141157) MMWR Morb Mortal Wkly Rep. 2021 Jan 15;70(2):46-51. (PMID: 33444297) MMWR Morb Mortal Wkly Rep. 2021 Jan 29;70(4):125-129. (PMID: 33507892) Am J Prev Med. 2020 Oct;59(4):493-503. (PMID: 32778354) J Infect Dis. 2021 Sep 17;224(6):938-948. (PMID: 33954775) MMWR Morb Mortal Wkly Rep. 2023 Feb 03;72(5):119-124. (PMID: 36730051) N Engl J Med. 2023 Feb 23;388(8):764-766. (PMID: 36734847) JAMA Netw Open. 2023 May 1;6(5):e2310650. (PMID: 37133863) Cost Eff Resour Alloc. 2011 Jan 21;9(1):1. (PMID: 21251294) Influenza Other Respir Viruses. 2023 Jan;17(1):e13062. (PMID: 36317297) N Engl J Med. 2021 Dec 2;385(23):2132-2139. (PMID: 34614329) Vaccine. 2011 Mar 3;29(11):2149-58. (PMID: 21215340) Scand J Prim Health Care. 2022 Sep;40(3):342-349. (PMID: 36314555) Vaccines (Basel). 2022 Apr 30;10(5):. (PMID: 35632467) Lancet. 2020 Aug 15;396(10249):467-478. (PMID: 32702298) Lancet. 2022 Mar 5;399(10328):924-944. (PMID: 35202601) JAMA. 2022 Oct 18;328(15):1523-1533. (PMID: 36255426) Int J Infect Dis. 2022 Sep;122:636-643. (PMID: 35811082) MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):146-152. (PMID: 35085225) N Engl J Med. 2022 Mar 31;386(13):1207-1220. (PMID: 35172051) PLoS Comput Biol. 2021 Jan 7;17(1):e1008470. (PMID: 33411742) Lancet. 2020 Aug 15;396(10249):479-488. (PMID: 32702299) PLoS One. 2020 May 13;15(5):e0232168. (PMID: 32401751) Am J Prev Med. 2021 May;60(5):605-613. (PMID: 33632650) N Engl J Med. 2020 Dec 17;383(25):2427-2438. (PMID: 32991794) MMWR Morb Mortal Wkly Rep. 2024 Feb 01;73(4):77-83. (PMID: 38300853) MMWR Morb Mortal Wkly Rep. 2022 Aug 26;71(34):1085-1091. (PMID: 36006841) Vaccines (Basel). 2022 Jun 30;10(7):. (PMID: 35891214) J Glob Health. 2023 Jan 14;13:06001. (PMID: 36637810) Int J Environ Res Public Health. 2023 Jan 16;20(2):. (PMID: 36674367) PLoS One. 2022 Jan 31;17(1):e0263014. (PMID: 35100309) Vaccines (Basel). 2022 Jul 03;10(7):. (PMID: 35891232) |
| معلومات مُعتمدة: | P01 AI172725 United States AI NIAID NIH HHS; 2054858 National Science Foundation; U54TR004279 United States NH NIH HHS; 1R01HS028165-01 Agency for Healthcare Research and Quality; City University of New York; R01GM127512 United States GM NIGMS NIH HHS; R01 HS028165 United States HS AHRQ HHS; United States TR NCATS NIH HHS; National Institute of Allergy and Infectious Diseases; R01 GM127512 United States GM NIGMS NIH HHS |
| فهرسة مساهمة: | Keywords: COVID-19; booster; economic; individual; model; vaccination |
| المشرفين على المادة: | 0 (COVID-19 Vaccines) |
| تواريخ الأحداث: | Date Created: 20240406 Date Completed: 20240815 Latest Revision: 20240817 |
| رمز التحديث: | 20240817 |
| مُعرف محوري في PubMed: | PMC11326810 |
| DOI: | 10.1093/infdis/jiae179 |
| PMID: | 38581432 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1537-6613 |
|---|---|
| DOI: | 10.1093/infdis/jiae179 |